AstraZeneca and Amgen said their experimental asthma drug tezepelumab failed to meet the main goal of reducing patients’ dependence on steroids, while keeping the respiratory condition in check in a late-stage trial.
https://www.pharmalive.com/wp-content/uploads/2020/06/AstraZeneca-Moderna-ahead-in-COVID-19-vaccine-race-WHO-Reuters-6-26-20.jpeg246370Andrew Humphreyshttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngAndrew Humphreys2020-12-22 02:35:242020-12-22 12:19:46AstraZeneca-Amgen drug fails main goal of late-stage asthma study